Variational, which offers blockchain-based derivatives tied to cryptocurrencies and traditional assets, raised a $110M Series B at a $1.5B valuation (Jason Shubnell/The Block)
Variational has secured $110 million in a new Series B funding round that values the company at $1.5 billion. The platform delivers blockchain-based derivatives linked to both cryptocurrencies and traditional assets. By utilizing distributed ledger technology, the firm bridges decentralized tokens with conventional market structures. The milestone funding event was officially reported by Jason Shubnell for The Block.
Key points
The platform uses blockchain-based infrastructure to bridge conventional financial market…: The platform uses blockchain-based infrastructure to bridge conventional financial markets with digital assets.
Achieving a $1.5 billion valuation establishes the derivatives trading company as a promi…: Achieving a $1.5 billion valuation establishes the derivatives trading company as a prominent new unicorn.
The successful Series B round was publicly reported by Jason Shubnell for The Block.: The successful Series B round was publicly reported by Jason Shubnell for The Block.
Sources checked by our analysis pipeline: 1
Jason Schreier / Bloomberg: |
Wesley Yin-Poole / IGN: |
Alessio Palumbo / Wccftech: |
Jason Schreier / Bloomberg: |
Jeff Stein / The Washington Sun: |
Bloomberg: |
Kiki Intarasuwan / CBS News: |
Nvidia Newsroom: |
The Information: |
Tim Fernholz / TechCrunch: |
Sam Kriss / New Yorker: |
Semafor: |
Wall Street Journal: |
Hayden Field / The Verge: |
Center for AI Safety: |
Brunella Tipismana Urbano / The Point Magazine: |
Nick Indge / Ars Technica: |
Ina Fried / Axios: |
Alexandra Alper / Reuters: |
New York Times: |
Juro Osawa / The Information: |
The Information: |
Katie McQue / NPR: |
Jason Parham / Wired: |
Sergiu Gatlan / BleepingComputer: |
This is a Techmeme archive page. It shows how the site appeared at 11:20 AM ET, November 18, 2026.
The most current version of the site as always is available at our home page. To view an earlier snapshot click here and then modify the date indicated.
Investors responded sharply to the latest clinical update, driving down shares of Innate Pharma in market trading. The downturn followed the formal publication of initial findings from an ongoing phase 1 trial. Market participants actively reassessed the company's prospects immediately after reviewing the newly disclosed early-stage study results.
Hyster-Yale shares have fallen sharply following the company's announcement of a planned $125 million debt offering. The stock dropped as investors reacted to the new financing plan.
Financial markets experienced widespread adjustments as sovereign debt drew persistent demand over multiple sessions. Concurrently, equities and crude energy prices moved downward, reflecting broader shifts in asset allocation across trading desks. These movements underline an evolving appetite among participants assessing current asset valuations and market conditions.